Tunlametinib is a pharmaceutical drug for the treatment of cancer. It is an inhibitor of mitogen-activated protein kinase kinase.
In China, tunlametinib was approved in 2024 for the treatment of patients with NRAS-mutated advanced melanoma who were previously treated with a PD-1/PD-L1 targeting agent.
It is also being studied for use in combination with vemurafenib in patients with advanced BRAF V600-mutant solid tumors.